Prognostic relevance of MYD88 mutations in CLL: the jury is still out

Blood. 2015 Aug 20;126(8):1043-4. doi: 10.1182/blood-2015-05-648634.

¹ Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
² Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece.
³ Università Vita-Salute San Raffaele, Milan, Italy Division of Experimental Oncology, Department of Onco-Hematology, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute, Milan, Italy.
⁴ Division of Haematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
⁵ Central European Institute of Technology, Masaryk University, Brno, Czech Republic University Hospital Brno, Brno, Czech Republic.
⁶ Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece Hematology Department, Hematopoietic Cell Transplantation Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
⁷ Università Vita-Salute San Raffaele, Milan, Italy Division of Experimental Oncology, Department of Onco-Hematology, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele, Milan, Italy.

No abstract available

Publication types